Clinical trials
Atypical Hemolytic Uremic Syndrome clinical trials
Below are recruiting atypical hemolytic uremic syndrome clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07399730Recruiting
Study of ravulizumab outcomes in Polish aHUS patients
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
GdanskAges 18 years+ - NCT04745195Recruiting
Study of complement activity in microangiopathy affecting kidneys
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
Maastricht, LimburgAges 18 years+ - NCT05795140RecruitingPhase 3
Long-term safety study of iptacopan for aHUS
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
São Paulo, São PauloAges 18–100 - NCT05805202Recruiting
Study rare gene changes in atypical HUS for tailored care
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
Ranica, BGAges Any age - NCT05935215RecruitingPhase 3
Switch from anti-C5 shots to iptacopan for aHUS
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
Nanjing, JiangsuAges 18–100 - NCT05996731Recruiting
Using RNA tests to help diagnose rare genetic diseases
This study uses RNA sequencing to find genetic causes of rare diseases that standard DNA tests might miss. It may help people who have symptoms of a rare disease but no clear genetic diagnosis yet.
Ranica, BGAges Any age - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age - NCT07308574RecruitingPhase 4
Ravulizumab for aHUS patients
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
Bunkyō CityAges 18 years+ - NCT01522183Recruiting
Registry for people with atypical hemolytic uremic syndrome
This is a registry that collects information from people diagnosed with atypical hemolytic uremic syndrome (aHUS). It helps researchers better understand the condition across different genetic causes and treatment needs.
Aurora, ColoradoAges Any age - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT05219110Recruiting
More fluids for children sick with toxin E. coli
This study looks at whether giving extra (hyper) fluids early helps children with a high-risk E. coli stomach infection. The goal is to improve outcomes by supporting the kidneys during the illness.
Birmingham, AlabamaAges 9 months–21 years - NCT06389474RecruitingPhase 3
Testing a new treatment for children with a serious kidney condition
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
Bahía Blanca, Buenos AiresAges 9 months–17 years
Hear when a new Atypical Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atypical hemolytic uremic syndrome?
- Yes. Clin2 currently lists 13 recruiting atypical hemolytic uremic syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atypical hemolytic uremic syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atypical hemolytic uremic syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.